세계의 위마비 치료제 시장 규모는 2024년 67억 달러에 달했습니다. IMARC Group은 향후 시장 규모가 2033년까지는 98억 달러에 이를 전망이며, 2025-2033년 4.06%의 성장률(CAGR)로 성장할 것으로 예측했습니다. 당뇨병성 위마비의 유병률 상승, 약물 개발 기술의 진보, 헬스케어 전문가 및 환자의 의식 향상, 의료 투자의 급증, 임상시험 증가, 당뇨병 및 파킨슨병 등 만성 질환의 급증, 규제 지원 등이 시장 성장을 뒷받침하는 요인의 일부입니다.
위마비 유병률 증가
특히 당뇨병 환자에서 위마비의 유병률 상승이 시장 성장을 가속화하고 있습니다. 2021년 인도의 20-79세 당뇨병 환자 수는 약 7,490만 명으로, 2045년에는 1억 2,490만 명에 이를 것으로 예측됩니다. 또한, 당뇨병 환자 증가로 효율적인 치료와 관리의 필요성이 급증하고 있으며, 이는 시장 성장에 큰 추진력을 부여하고 있습니다. 또한, 주요 제약 회사는 새로운 표적 치료의 개발에 적극적으로 노력하고 있으며, 이는 시장 전망을 더욱 밝게 만듭니다.
의약품 개발 기술의 진보
파이프라인에 있는 제품 수 증가 및 신제품 변형의 개발이 시장 개척을 뒷받침하고 있습니다. 게다가 위마비 치료제의 효능과 안전성을 향상시키기 위한 의약 연구 개발(R&D)에 대한 투자가 급증하고 있는 것도 시장 개척에 박차를 가하고 있습니다. 위마비 치료제 시장의 최근 기회로는 고처리량 스크리닝, 계산 의학, 맞춤형 의료 등의 출현으로 잠재적인 후보 화합물을 정확하고 신속하게 동정할 수 있게 된 것이 시장 성장에 탄력을 주고 있습니다. 이와는 별도로, 서방형 제제 및 신규 약물 전달 기구 등 약물 전달 시스템의 진보가, 약물의 효율적인 투여와 흡수를 실현해, 시장 성장을 뒷받침하고 있습니다.
헬스케어 전문가 및 환자 의식 증가
위마비에 대한 헬스케어 전문가와 환자의 의식이 높아짐에 따라 시장 성장이 크게 촉진되고 있습니다. 위마비 환자는 후속 인지도의 향상으로 더 정확하게 진단되고 시장 성장에 큰 추진력을 부여합니다. 또한, 소화기 전문의와 같은 헬스케어 전문가는 증상을 더 날카롭게 인식하고 위마비를 더 빨리 인식하며 더 나은 환자 관리로 이어집니다. 게다가 위마비의 증상과 치료에 대한 환자의 의식 증가와 새로운 치료 옵션의 가용성은 위마비 치료제 수요를 촉진하고 있습니다.
The global gastroparesis drugs market size reached USD 6.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.06% during 2025-2033. The rising prevalence of diabetic gastroparesis, advancements in drug development technologies, increasing awareness among healthcare professionals and patients, burgeoning healthcare investments, growing clinical trials, surging chronic conditions like diabetes and Parkinson's, and regulatory support are some of the factors propelling the market growth
Increasing Prevalence of Gastroparesis
The escalating prevalence of gastroparesis, especially in diabetes patients, is accelerating the market growth. In 2021 India had about 74.9 million people with diabetes aged between 20-79, which is expected to reach 124.9 million by 2045. Moreover, the increasing number of patients with diabetes has burgeoned the need for efficient treatment and management, which is further providing a considerable thrust to the market growth. Additionally, the key pharmaceutical companies are actively working to develop new and targeted therapy options, which is further creating a positive outlook for the market.
Advancements in Drug Development Technologies
The growing number of products in the pipeline and the development of new product variants are augmenting the market growth. Furthermore, the surging investments in pharmaceutical research and development (R&D) to improve the efficacy and safety of gastroparesis therapies are fueling the market growth. The gastroparesis drugs market recent opportunities, such as the advent of high-throughput screening, computational and personalized medicine, enabling precise and quick identification of potential candidates are providing an impetus to the market growth. Apart from this, the advancements in drug delivery systems, such as extended-release formulations and novel drug-delivery mechanisms, are rendering an efficient administration and absorption of medications, thereby impelling the market growth.
Rising Awareness Among Healthcare Professionals and Patients
The growing awareness among both healthcare professionals and patients regarding gastroparesis is significantly facilitating the market growth. Patients with the condition are more accurately diagnosed due to the subsequent increase in awareness, which further provides a considerable thrust to the market growth. Additionally, healthcare professionals, such as gastroenterologists, are becoming more acutely aware of the symptoms, which further helps recognize gastroparesis sooner, leading to better patient care. Moreover, burgeoning patient awareness about the symptoms and treatment of gastroparesis and the availability of novel treatment options are propelling the gastroparesis drugs demand.
Idiopathic gastroparesis accounts for the majority of the market share
The idiopathic gastroparesis segment is driven by the growing recognition of the condition's impact and the need for effective treatment solutions. Idiopathic gastroparesis, where no underlying cause can be identified, poses significant challenges for patients and healthcare providers due to its unpredictable nature and severity. Increased awareness and understanding of idiopathic gastroparesis among clinicians are leading to more accurate diagnoses and a focus on developing targeted therapies. Advances in diagnostic technologies, such as improved imaging and motility testing, are enhancing the ability to identify idiopathic gastroparesis cases and differentiate them from other gastrointestinal disorders, thereby boosting the gastroparesis drugs market growth. Furthermore, the rise in research funding and clinical trials dedicated to idiopathic gastroparesis is driving innovation in drug development, leading to new therapeutic options.
Prokinetic agents hold the largest share of the industry
The prokinetic agents segment in the gastroparesis drugs market is driven by several key factors, such as the increasing prevalence of gastroparesis, particularly among diabetic and elderly populations, which creates a strong demand for effective prokinetic therapies. Prokinetic agents, which enhance gastric motility and facilitate stomach emptying, are essential in managing the symptoms of gastroparesis, including nausea and vomiting. Significant advancements in drug development leading to improved prokinetic formulations with enhanced efficacy and fewer side effects are boosting gastroparesis drugs market revenue. The ongoing research and clinical trials focused on prokinetic agents contribute to a better understanding of their mechanisms and potential benefits, thereby expanding their clinical applications. Additionally, the growing awareness of gastroparesis among healthcare professionals and patients underscores the need for effective treatments, further driving the demand for prokinetic agents.
Hospitals and clinics represent the leading market segment
The hospitals and clinics segment in the gastroparesis drugs market is driven by the increasing demand for specialized medical care and advanced treatment options for managing gastroparesis. The segment benefits from the escalating prevalence of gastroparesis, particularly among diabetic patients, necessitating more comprehensive and frequent medical interventions. Hospitals and clinics offer a range of diagnostic and therapeutic services, including specialized gastroenterology departments and advanced imaging technologies, which are crucial for accurate diagnosis and effective management of gastroparesis. Additionally, the rise in chronic conditions such as diabetes and Parkinson's disease, which often lead to gastroparesis, further drives the need for hospital-based treatments.
North America leads the market, accounting for the largest gastroparesis drugs market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for gastroparesis drugs.
The North America regional market is driven by the burgeoning prevalence of gastroparesis, particularly among the diabetic population, which significantly impacts demand for effective treatments. The high incidence of diabetes is a major contributing factor, as diabetic gastroparesis is a common complication. Additionally, the gastroparesis drugs market recent developments and advancements, such as high-throughput screening and novel drug delivery systems, enhancing the efficacy and safety profiles of gastroparesis medications are aiding in market expansion. Besides this, the region also benefits from robust healthcare infrastructure and significant investments in research and development, enabling faster introduction of innovative treatments. Moreover, the increasing awareness among healthcare professionals and patients about gastroparesis and its management is strengthening the market growth, leading to earlier diagnosis and more proactive treatment approaches.